PDCD1 and cancer: Indeed, oncolytic herpes simplex virus, which was the first United States Food and Drug Administration-approved treatment for advanced melanoma, showed synergistic anti-cancer activity with anti-PD-1 immunotherapy by promoting intratumoral T cell infiltration [6].